Nuveen Asset Management, LLC Magenta Therapeutics, Inc. Transaction History

Nuveen Asset Management, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.97 - $3.08 $68,548 - $217,660	-70,669 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$4.43 - $8.33 $82,796 - $155,687	-18,690 Reduced 20.92%	70,669 $339,000
Q3 2021 Nov 12, 2021	BUY	$6.07 - $9.89 $7,878 - $12,837	1,298 Added 1.47%	89,359 $697,000
Q2 2021 Aug 16, 2021	SELL	$9.76 - $14.15 $477,742 - $692,628	-48,949 Reduced 35.73%	88,061 $861,000
Q1 2021 May 17, 2021	SELL	$7.66 - $13.38 $50,939 - $88,977	-6,650 Reduced 4.63%	137,010 $1.62 Million
Q4 2020 Feb 16, 2021	BUY	$6.1 - $7.94 $92,573 - $120,497	15,176 Added 11.81%	143,660 $1.13 Million
Q3 2020 Nov 16, 2020	BUY	$6.52 - $8.94 $410,877 - $563,380	63,018 Added 96.26%	128,484 $873,000
Q2 2020 Aug 14, 2020	SELL	$6.18 - $10.76 $13,280 - $23,123	-2,149 Reduced 3.18%	65,466 $492,000
Q1 2020 May 14, 2020	BUY	$6.03 - $15.24 $96,859 - $244,800	16,063 Added 31.16%	67,615 $424,000
Q4 2019 Feb 14, 2020	SELL	$9.07 - $15.84 $15,146 - $26,452	-1,670 Reduced 3.14%	51,552 $782,000
Q2 2019 Aug 15, 2019	BUY	$13.4 - $17.67 $713,174 - $940,432	53,222 New	53,222 $785,000

442K

Ticker MGTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,890,500
Description
Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops medicines to bring the curative power of stem cell transplants to patients with blood cancers, genetic diseases, and autoimmune diseases. It develops MGTA-117, an anti-CD117 antibody that targets hematopoietic stem cells (HSCs) and genetically mutated stem cells that ca...

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Nuveen Asset Management, LLC with notifications on news.